[ad_1]
A team of Israeli researchers said that they had reached a "complete cure" for cancer.
"We believe we will provide comprehensive cancer treatment within one year," said Dan Eridor of AEBi, who developed the treatment.
The new treatment is called MuTaTo, according to ERDOR, president of AEBi and CEO, Ilan Murad. Multipurpose toxin is a powerful antibiotic against cancer.
The anticancer drug is based on a technique called Soap, which involves inserting specific DNA codes into bacterial viruses called Bacteriophage, which in turn can replicate the proteins used in the treatment of cancer.
The mechanism of action of this drug is similar to that for which an American scientist won the Nobel Prize in Chemistry in 2018. It relies on the production of antibodies to treat a number of chronic diseases, including the cancer.
The Israeli team however used compounds of at least two amino acids (peptides) rather than antibodies.
According to Murad, peptides have more advantages than antibodies, especially their small size, low price and ease of production.
The researchers reported using the peptide method after finding that current cancer drugs and therapies were not working or did not eliminate the cancer.
What sets MuTaTo apart is that it simultaneously uses a set of cancer target peptides in each cancer cell, combined with a strong protein toxin (proteinuria) that kills cancer cells.
"We have made sure that the treatment of the mutations is not affected," said Murad, as cancer cells transform and produce new cell receptors that do not respond to the first treatment used in cancer treatment.
Another benefit of the new drug is its ability to kill cancer cells before it disrupts its function (by extrusion or altering its physiological pathway).
Unlike many cancer treatments targeting fast-growing cells, the new drug can target stem cells at the origin of cancer, researchers said.
Some cancerous tumors build shields that prevent the arrival of current treatments (large molecules), but the new drug (MuTaTo) works "like an octopus and can sneak into places that other large molecules can not not reach, "according to Murad, who explained that some parts of the peptide are too small. With a length of 12 amino acids.
According to this study, this feature "renders the entire molecule fully immunized against the immune system in most cases and allows repeated use of the drug".
"The drug has minor or no side effects because it is highly specific for cancer cells," said Murad. Explaining that it will be issued in the form of a generic drug, and other personnel, depending on the type of cancer.
According to Murad, their company ended its first exploratory experiment on mouse tests and "succeeded in preventing the growth of human cancer cells and has no effect on healthy rat cells".
The company is about to start a new series of clinical trials that can be completed in a few years and to offer treatments in specific cases.
"Our results are consistent and reproducible," said Dan Eridor of AEBi.
An estimated 18.1 million cancer cases worldwide each year, according to the International Agency for Research on Cancer.
In addition, cancer is the second leading cause of death after cardiovascular disease.
Source link
